Kornimate/medical-research-clean huggingface dataset:
psychological intervention mobile app for patients with aml

Conditions: Acute Myeloid Leukemia

Summary: this research study is evaluating the impact of a psychological intervention mobile application (app) on the quality of life, mood, and symptoms of patients with acute myeloid leukemia (aml).

patients with a new diagnosis of aml often confront a sudden and life-threatening diagnosis, requiring an immediate disruption of their life and an urgent 4-6 week hospitalization to initiate intensive chemotherapy. during this hospitalization, they endure substantial physical symptoms due to the side-effects of intensive chemotherapy, which negatively impacts their quality of life (qol). patients with aml also experience significant psychological distress as they struggle with the abrupt onset of illness, uncertainty regarding their prognosis, physical and social isolation during their hospitalization, and complete loss of independence. the study doctors want to know if the use of a mobile application (app) focused on helping patients cope with the diagnosis and treatment can reduce the distressing symptoms and improve the their quality of life and care. the main purpose of this research study is see if a mobile app is feasible to use for patients with new diagnosis of aml and is acceptable to them. the study will also compare two types of care - standard leukemia care and standard leukemia care with the mobile app to see which is better for improving the experience of patients newly diagnosed with aml undergoing treatment. the purpose of this research study is to find out whether using the mobile app that is focused on educating patients about leukemia and how to cope with its treatment can improve the physical and psychological symptoms that patients experience during hospitalization for their leukemia care. using this research, the study doctors hope to find out the best way to help patients cope with their diagnosis and treatment for acute myeloid leukemia. the study will use questionnaires to measure patient's quality of life, physical symptoms, mood, and the participant sense of control over their situation. study questionnaires will be completed in the hospital or clinic with assistance provided as needed. the participants will also have the option of completing these questionnaires remotely through a secure web link or through a mailed paper copy

Eligibility criteria:
inclusion criteria: * adult patients (≥18 years). * new diagnosis of acute myeloid leukemia. * admitted to massachusetts general hospital for intensive induction chemotherapy requiring 4-6-week hospitalization. * the ability to provide informed consent. * ability to comprehend and speak english. exclusion criteria: * significant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder, * major depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits the ability to participate in study procedures

Keywords: acute myeloid leukemia
performance of bioresorbable scaffold in primary percutaneous intervention of st elevation myocardial infarct

Conditions: Acute ST Segment Elevation Myocardial Infarction

Summary: patients presenting with acute st elevation myocardial infarct urgently need revascularization. standard of care is establishing bloodflow through the coronary vessels using thrombus aspiration catheter, and securing the result by using a metallic drug eluting stent. new kinds of non-metallic bioresorbable stents are now available. they have however challenges in structural strength. the investigators want to compare the new bioresorbable scaffold with traditional metallic stents in this setting in a prospective, randomized, non-blinded, multicenter study in 120 patients. the investigators will use an imaging technique, optical coherence tomography, to evaluate the results after 12 months. the investigators also want to see if modern multislice computed tomography can give useful information in the follow-up of stented coronary arteries after 12 and 24 months.

patients presenting with st elevation myocardial infarction for primary pci (percutaneous coronary intervention) will be screened. after thrombus aspiration, patient will be asked for oral consent if timi flow 2-3. patient will then be randomized between drug eluting stent (xience pro, abbott vascular solutions) and bioresorbable scaffold (absorb, abbott vascular solutions). optical coherence tomography (oct) will be performed before stenting and after final result. stent will be deployed without further predilatation if possible. follow up at 12 months (clinical, angio with oct and multislice ct coronary angiogram (msct-ca)) and 24 months (msct-ca).

Eligibility criteria:
inclusion criteria: 1. history of chest pain \< 12 hrs 2. st elevation of ≥ 2 mm in ≥2 contiguous precordial leads (v1-v6), and/or ≥ 1 mm in ≥ 2 contiguous standard leads (i, ii, iii, avf, avr,avl). 3. clinical decision to treat with primary pci 4. \> 18 years 5. oral informed consent exclusion criteria: 1. contraindications to long term double antiplatelet therapy 2. known kidney failure with gfr \< 45 3. cardiac arrest or severe cardiogenic shock (persistent bp \<90 mmhg, despite adequate treatment) 4. other severe illness with life expectancy of less than 12 months (eg. malignancy, severe malnutrition, degenerative disease) procedural contraindications: 1. heavy calcification, tortuous vessel or large side branch (\> 2,5 mm) at culprit lesion. 2. timi 0-1 flow after aspiration 3. unable to advance thrombus aspiration catheter

Keywords: stemi coronary bioresorbable scaffold drug eluting stent optical coherence tomography multislice computed tomography
a weight loss trial for emotional eating

Conditions: Obesity

Summary: the purpose of this study is to determine whether a new weight loss treatment which incorporates behavioral weight loss skills and skills for learning how to identify, manage, and cope with emotions helps with weight loss and emotional eating in people who are overweight and eat in response to emotions.


Eligibility criteria:
inclusion criteria: * non-smoker, free of diabetes, overweight and interested in losing weight, eat in response to emotions exclusion criteria: * diabetes, any major medical or psychiatric condition that would compromise ability to participate, hypertension, current mental health treatment
prospective/retrospective registry of the e-vita open plus stent graft system in france

Conditions: Vascular Diseases

Summary: the feor registry is undertaken to examine the real-world data of patients that were treated with the e-vita open plus stent graft system under routine care in france. this registry is a requirement of the haute autorité de santé (has).

data collection on patients who have been implanted with an e-vita open plus stent graft system from 15th july 2014 until 31st may 2019. the e-vita open plus stent graft system was implanted at the discretion of the treating physician. participating physicians provided their observations collected during routine care for patients he/she had decided to treat with the e-vita open plus stent graft system. the period of data collection was three years starting from the intervention of each patient. data verification was performed.

Eligibility criteria:
inclusion criteria: none exclusion criteria: none

Keywords: aortic aneurysms aortic dissections thoracic
amblyopia and strabismus detection using a pediatric vision scanner

Conditions: Amblyopia; Strabismus

Summary: the purpose of this project is to compare the performance of the pediatric vision scanner (pvs) with the gold standard examination to determine the effectiveness of the pvs at detecting amblyopia and strabismus. all tests and observations will be done at a single visit over the course of approximately 30 minutes.


Eligibility criteria:
inclusion criteria: * children aged 6 months to 6 years * signed informed consent by parent or guardian * meet all inclusion criteria. exclusion criteria: * children with a history of developmental delay or cognitive deficit * children unable to complete the gse (including visual acuity testing)
role of indoor pollutants on house dust mite allergic asthma

Conditions: Allergic Asthma; Allergy to House Dust Mite

Summary: it seems that the aldehydes and no2, at the levels found indoor, could be the aggravating factors for an allergic response. however this effect has not been demonstrated. the investigators plan to study the effect of exposure to standard doses of these pollutants on the bronchial reactivity as measured by bronchial challenge tests with dust mite extract in volunteers asthmatic, allergic to house dust mite.


Eligibility criteria:
inclusion criteria: * m/f 18-50 years of age * history of intermittent hdm allergic asthma-fev1 \> 80% * non smokers or smokers with smoking \< 10 py exclusion criteria: * persistent asthma and fev1\<80% * allergic to pets and pets at home

Keywords: indoor pollutants
efficacy of biosimilar filgrastim on the mobilization of hematopoietic stem cell cd34+ (cluster of differentiation 34) and on the kinetic engraftment

Conditions: Blood Diseases

Summary: the endogenous growth factor granulocyte (g-csf) stimulates the proliferation and differentiation of hematopoietic progenitors commissioned to mature as neutrophils and activated granulocytes mature neutrophils. in the field of hematology oncology g-csf it is used to reduce the duration and complications of chemotherapy-induced neutropenia and to stimulate the mobilization and subsequent collection of circulating hematopoietic stem cells in order to use them for autologous transplantation procedure. filgrastim and lenograstim originator are marketed for many years and are considered the reference molecules for the production of biosimilar. for several years it is available and entered into common clinical practice the use of filgrastim biosimilar (bio-gcsf) in treating the patient oncohematologic. aim of the study is to analyze retrospectively a large series of patients and assess the impacts of the bio-gcsf on the collection of hematopoietic stem cells and recovery of blood counts post autologous transplantation; the data will be compared with a historical cohort of reference that has been treated with g-csf originator. the study results will not generate any diagnostic or therapeutic intervention in patients still alive.


Eligibility criteria:
inclusion criteria: * \> 18 years with history of autologous transplant * hematological diseases including: * multiple myeloma * hodgkin's lymphoma * non-hodgkin lymphoma b and t * lymphocytic leukemia * acute myeloid leukemia exclusion criteria: * n.a.

Keywords: patients
cohort of heart failure patients

Conditions: Congestive Heart Failure

Summary: this is a prospective cohort study of patients with heart failure with an eighteen-month follow-up aimed to collect all demographic, clinical, biological and para-clinical data to study population characteristics, assess prognosis markers and occurrence of hf treatment side effects. congestive heart failure is a frequent pathology and its prevalence increases with age. its prognosis stays pejorative despite years of major therapeutical progress. in recent trials, all-cause mortality rates at 1-year reach up to 20% and 50% at 5 years. medical care of congestive heart failure is based on precise international recommendations. the association of beta-blockers, renin-angiotensin system blockers, mineralocorticoid receptor antagonists, represent the basis of the pharmacological treatment. cardiac resynchronization treatment and implantable cardioverter-defibrillator are additional efficient treatments that reduce events in appropriately selected patients. despite these improvements, the prognostic of congestive heart failure in registers is worse than those observed in randomized trials. this can be explained by differences in congestive heart failure patient populations and/or by a less rigorous medical care where treatments are not optimized. the evaluation of medical care in congestive heart failure is today of utmost importance. integrating new pharmacological molecules, medical devices and the application of new recommendations have major interest for documentation and practical changes. the main objective of this cohort will be to evaluate the evolution of the 12-month quality of life score of a hf patient and the characteristics and treatments associated with it.


Eligibility criteria:
inclusion criteria: * patients with congestive heart failure confirmed during * hospitalization for cardiac decompensation * a medical follow-up for stable congestive heart failure with at least one cardiac decompensation event * nt-probnp \> 500 ng/l in the month before baseline (or bnp \> 150 ng/l) * nyha ≥ 2 * aged over 18 * signature of the informed consent exclusion criteria: * life expectancy shorter than a month * patients on long term assistance or with heart transplant * impossibility to give patients clear information * loss of autonomy, dementia, major dependence * patients without health coverage * patient with no legal protection * pregnant woman

Keywords: heart failure heart diseases cardiovascular diseases vascular diseases cohort
effect of game based approach on oxygenation, functional capacity and quality of life in primary ciliary dyskinesia

Conditions: Primary Ciliary Dyskinesia; Kartagener Syndrome; Immotile Cilia Syndrome

Summary: impaired pulmonary function, decreased physical activity, functional capacity and depending on these factors are reported in patients with primary ciliary dyskinesia in recent studies. the purpose of this study to evaluate the effects of game based approach on pulmonary function, functional capacity and quality of life in patients with primary ciliary dykinesia.

primary ciliary dyskinesia (pcd) is an autosomal recessive hereditary disorder characterized by congenital structural abnormalities and impairment of respiratory function. mucociliary clearance is affected by disorders in the structure and movement of cilia. that causes repeated infections in the upper and lower respiratory tract.in addition to mucociliary effects and impaired lung function, it is thought that there may be a decrease in respiratory muscle strength and functional capacity. one of the factors affecting functional capacity is the level of physical activity. for these reasons, the management of the respiratory system in patients with pcd is very important. in addition to airway clearence techniques, approaches to increase physical activity are also important. it was thought that severe physical activity could be an important determinant of cardiopulmonary functional capacity in patients with mild to moderate pcd. the level of physical activity is known to be associated with quality of life. in literature no study investigated the effects of game based approach on oxygenation, functional capacity and quality of life in patients with pcd. game based approach is a new method lead to increase physical activity. in literature there is no study investigated the effects of game based approach on oxygenation, functional capacity and quality of life in patients with pcd.

Eligibility criteria:
inclusion criteria: * being diagnosed with pcd * being clinically stable * between 6-18 years old * volunteer to participate in research exclusion criteria: * not having a stable clinical condition * patients with severe neuromuscular, musculoskeletal and rheumatological problems * patients with loss of balance * not being cooperative

Keywords: primary ciliary dyskinesia kartegener syndrome immotile cilia syndrome pulmonary rehabilitation airway clearance techniques exergame
exercise testing in peripheral artery disease patients

Conditions: Peripheral Artery Disease

Summary: the aim of this study was to evaluate exercise testing in case of patients suspected of peripheral artery disease (pad).

this is a non interventional prospective cross sectional, monocentric study. all patients addressed in our vascular unit for exercise testing were included. all patients' data performed in clinical routine can be analyzed.

Eligibility criteria:
inclusion criteria: * all patients addressed in our vascular unit for exercise limitation exclusion criteria: * incapacity to walk on the treadmill. * a severe cardiopathy contraindicating a stress test
comparison of dequalinium chloride (fluomizin) vs oral metronidazole for the treatment of bacterial vaginosis

Conditions: Bacterial Vaginosis; Vaginal Infection; Vaginal Diseases

Summary: the goal of this clinical trial is to show the efficacy and safety of dequalinium chloride in the treatment of bacterial vaginosis compared to metronidazole.

eligible patients who signed informed consent were randomized to receive treatment with either dequalinium chloride (+ oral placebo) or metronidazole (+ vaginal placebo) for up to 7 days. primary objective was clinical cure rate at one week after start of treatment. control visits to assess outcomes were done after end of treatment and after one month.

Eligibility criteria:
inclusion criteria: 1. premenopausal woman ≥18 years 2. diagnosis of bacterial vaginosis (all 4 amsel criteria positive, i.e. 1) greyish white thin discharge, 2) postassium hydroxide (koh) test or 'fishy' smell, 3) microscopic presence of \> 20% clue cells, 4) vaginal ph \> 4.5) 3. signed written informed consent to participate in this study exclusion criteria: 1. pregnancy and/or lactation based on urine pregnancy test (women with childbearing potential should use any contraception excluding vaginal methods like vaginal ring, etc.) 2. uterine bleeding (including menstruation) or vaginal bleeding of unknown origin 3. ulcerations/erosions of vaginal mucosa or cervix uteri 4. patients with clinical symptoms and findings of candida vulvovaginitis and/or aerobic vaginitis 5. clinically manifest or suspicion of sexually transmitted infections (neisseria gonorrhoeae, chlamydia trachomatis, or trichomonas vaginalis) based on signs, symptoms, and anamnesis 6. use of any antimicrobial treatment (local or systemic) 14 days before entry the study 7. use of any vaginal medication or vaginal douching 7 days before entry the study 8. unwillingness to refrain from alcohol consumption during treatment, and 48 hours after treatment 9. severe systemic diseases (hiv, cancer, tuberculosis, autoimmune diseases, diabetes mellitus, severe psychiatric conditions, etc.), including diseases treated with immunosuppressive therapies, systemic corticosteroids, or warfarin 10. known or suspected hypersensitivity to one of the study medications, inclusive of their excipients 11. inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant (including inability to fill-in electronic patient diary) 12. participation of patient in another investigational drug study concomitantly or within 30 days prior to entry in the study 13. patient is relative of, or staff directly reporting to, the investigator

Keywords: bacterial vaginosis dequalinium chloride metronidazole vaginal infection treatment comparative study non inferiority
computer-based training for mild alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the primary objective of this study is to evaluate the effects of computer-based training program ("hifi-ad") on the memory and cognitive abilities of individuals diagnosed with mild alzheimer's disease (ad).

the purpose of this study is to determine the extent to which computer-based cognitive remediation improves cognitive functions using standardized neuropsychological assessments relevant to ad; 2) the acceptability and feasibility of using computer-based cognitive remediation in an ad population.

Eligibility criteria:
inclusion criteria: * fluent in english. * mini-mental status examination (mmse) score of 22 or higher. * adequate visual capacity. * adequate hearing capacity. * has a caregiver with some computer experience. * willing and able to commit to the time requirement of the entire study. exclusion criteria: * clinically significant cerebrovascular disease. * participant is planning to begin acetylcholinesterase inhibitor (achei) therapy. * participants with severe tremor. * axis 1 or 2 psychiatric disorders. * history of substance abuse. * history of head trauma.

Keywords: alzheimer's ad mild cognitive impairment dementia cognitive remediation computer-based training
liposomal irinotecan and apatinib in es-sclc

Conditions: Small Cell Lung Cancer Extensive Stage

Summary: the purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.

small cell lung cancer is a highly invasive neuroendocrine tumor characterized by high malignancy and rapid proliferation. although most patients with extensive sclc are sensitive to first-line treatments such as etoposide combined with platinum and immunotherapy, most patients experience disease progression again after first-line treatment. therefore, extending the survival time of patients and improving their quality of life have become key issues in the second-line treatment of sclc. the current guidelines for second-line treatment of sclc recommend monotherapy, including topotecan, irinotecan, etc. however, the available options have poor efficacy and are prone to drug resistance. irinotecan liposomes improve drug stability and prolong circulation time through liposome encapsulation, and target tumor tissues through high permeability and long retention effects, with the expected effect of reducing toxicity and increasing efficacy. apatinib is a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors to achieve anti angiogenic and anti-tumor effects. it has been proven to have positive therapeutic effects in multiple types of cancer, including sclc. at present, the combination mode of chemotherapy and anti-angiogenic drugs has been explored in various tumors, and the results show that this mode has drug synergistic effects, which can significantly improve the efficacy of anti-tumor treatment. therefore, exploring the efficacy, safety, and mechanism of liposomal irinotecan combined with apatinib is of great clinical and theoretical significance for the refractory tumor population of extensive stage small cell lung cancer with first-line treatment progress.

Eligibility criteria:
inclusion criteria: 1. age range of 18-75 years; 2. expected survival period ≥ 12 weeks; 3. at least one measurable lesion (according to recist v 1.1); 4. for patients who have failed first-line or second-line treatment. exclusion criteria: 1. have received any systemic treatment targeting vegf or vegfr in the past, such as treatment with anti angiogenic drugs such as ranibizumab, fipronib, apatinib, anlotinib, lenvatinib, sunitinib, sorafenib. 2. active or uncontrolled severe infection (ctcae 5.0 ≥ 2) and/or antibiotic treatment within 2 weeks prior to enrollment; 3. there are multiple factors that affect the absorption of oral medication, such as inability to swallow, nausea and vomiting, chronic diarrhea, and intestinal obstruction; 4. those deemed unsuitable for inclusion by doctors;

Keywords: small cell lung cancer liposomal irinotecan apatinib
study evaluating etanercept in moderate to severe asthma

Conditions: Asthma

Summary: the primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.


Eligibility criteria:
inclusion criteria: * moderate to severe persistent asthma for at least 1 year * demonstrated reversibility of at least 9% and (fev1) 50% to 80% predicted * subjects must be on a high-dose inhaled corticosteroid (ics) exclusion criteria: * previous treatment with etanercept * current use of cigarettes * significant concurrent medical conditions at the time of screening

Keywords: asthma anti-asthmatic agents receptors tumor necrosis factor